StemCell Therapy

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UHs policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Mark Armando Prendes did not disclose any Outside Relationships with Industry.

Go here to see the original:
Mark Armando Prendes MD Doctor Profile & Reviews ...

This entry was posted on April 25, 2019 at 9:46 am and is filed under Opthalmology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |